Global Severe Combined Immunodeficiency (SCID) Diagnosis Market -2023-2030

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market -2023-2030

The Global Severe Combined Immunodeficiency (SCID) Diagnosis Market reached US$ 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 423.5 million by 2030. The global severe combined immunodeficiency (SCID) diagnosis market is expected to exhibit a CAGR of 10.4% during the forecast period (2023-2030). The increasing technological advancements and the growing investments for novel products are driving up demand for severe combined immunodeficiency (SCID) diagnosis market trends.

To identify severe combined immunodeficiency (SCID), a thorough medical history plus physical examination of the child are typically required. Additional blood tests, such as a total blood cell count, could be requested in order to verify the diagnosis. The launch of new products, and an increase in patients with immunodeficiency are the main factors propelling the global market for severe combined immunodeficiency (SCID) diagnosis.

The severe combined immunodeficiency (SCID) diagnosis market scope comprises test type as TREC, complete blood count (CBC), genetic test, biochemical test, others, which has increased the severe combined immunodeficiency (SCID) diagnosis market share. The global market for severe combined immunodeficiency (SCID) diagnosis is expanding as a result of factors including the increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the severe combined immunodeficiency (SCID) diagnosis market growth.

Market Dynamics

Increased Awareness of Diagnosis Procedures Drives the Growth of the Severe Combined Immunodeficiency (SCID) Diagnosis Market

SCID typically does not manifest clinically right away when a baby is born. This is due to the fact that preferably for the first few weeks, newborns with SCID live on developing immunity from mthe other's antibodies. But over time, babies are nonetheless affected by weakened microorganisms in vaccines like those for polio, chickenpox, rotavirus, BCG, and others because they lack an immune response.

When neonates reach an age between four and six months following the symptoms first appearing, SCID is typically diagnosed. Early intervention, when there is a risk owing to a family record of immunodeficiency might involve DNA sequencing of the fetus to check for any relevant gene changes.

Early detection of SCID during pregnancy allows for plenty of time for postpartum treatment. The next-best choice is newborn screening. Blood can be drawn at birth to identify B cells and T cells and determine their roles. Postnatal testing for DNA can be utilized for a more comprehensive diagnosis.

Increasing Incidence of Severe Combined Immunodeficiency (SCID) Disorder Creates Lucrative Opportunities for Manufacturers

Adenosine deaminase insufficiency is a very uncommon condition that affects only 1 in 200,000 to 1,000,000 babies globally. Around 15% of SCID instances are due to this disorder. An uncommon genetic disorder called SCID (severe combined immunodeficiency) results in life-threatening autoimmune abnormalities. It is a primary immunological symptom in some way.

In the United States, 1 in 58,000 neonates is born having SCID each year. A hereditary primary immunodeficiency disorder (PIDD) called severe combined immunodeficiency (SCID) frequently shows up in children and results in severe immunological insufficiency, leaving the body unable to fight off even small infections. It is considered to be the most severe PIDD.

Other varieties of SCID are caused by a variety of genetic disorders as well as a deficiency in the enzyme adenosine deaminase. Infants having SCID are prone to typical illnesses that affect healthy newborns. They are nonetheless more susceptible to illnesses brought on by microbes or live vaccines, which are typically safe for kids with healthy immune systems.

Delayed and Improper Diagnosis will Hamper the Growth of the Market.

However, infections are frequent in the general population of children due to the absence of a known family history, an absence of differentiating physical characteristics, and other factors. Unfortunately, when a patient has gone through a string of illnesses, most of which are serious, medical professionals only take the possibility of weakness in host defenses into account.

Sadly, infants with SCID who lack an older sister who is sick or another known affected family member are typically not detected until after numerous infections have taken place. These infections always have a significant influence on urgent medical care, family suffering, and long-term morbidity, while they occasionally result in death.

COVID-19 Impact Analysis

The financial health of companies across all industries was impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the interval of the COVID-19 health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global severe combined immunodeficiency (SCID) diagnosis market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global severe combined immunodeficiency diagnosis market growth over the forecast period.

Segment Analysis

The global severe combined immunodeficiency (SCID) diagnosis market is segmented based on disease type, test type, end user and region.

TREC from Test Type Segment Accounts for 32.8% of Market Share Owing to Rising Advantages

In Guthrie card dried blood spots (DBS), T-cell receptor excision circles (TRECs) can be quantified using real-time quantitative polymerase chain reaction (RT-qPCR), which enables early SCID detection. Low TRECs represent TCL since they are a DNA consequence of T cell receptor recombination.

Thus, SCID can be screened for using neonatal TREC levels to identify defective T cell development. After receiving a positive screen, diagnostic testing is necessary to confirm a precise genetic diagnosis and to ascertain whether the patient has typical SCID or another type of TCL.

The severity of the symptoms associated with SCID, the improved prognosis following a timely diagnosis, the accessibility of a screening test, along with proof that newborn screening (NBS) for SCID is financially viable, all serve to show that SCID satisfies the Wilson-Jungner criteria for screening and designate SCID as a suitable candidate for NBS.

Geographical Analysis

North America Accounted for Approximately 43.5% of the Market Share Owing to the Strong Presence of Major Players and the Advancements in Severe Combined Immunodeficiency (SCID) Diagnosis

Manufacturers have chances to expand their operations in this region because of the rising demand for severe combined immunodeficiency (SCID) diagnosis for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of severe combined immunodeficiency diagnosis, which has increased the demand.

There are many manufacturers and suppliers in North America, and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for research and development of novel products.

The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals, and the introduction of new products all contribute to growth. People are becoming more aware of novel instruments and technologies, leading to the expansion of the market in this region. These factors are responsible for the dominance of North America.

Competitive Landscape

The major global players in the severe combined immunodeficiency (SCID) diagnosis market include ARCHIMED Life Science GmbH, Revvity (PerkinElmer), Labsystems Diagnostics Oy, Revcovi, LaCAR MDx, Leadiant Biosciences, Inc., Winfertility, GSK Plc, CSL Behring and Devyser Diagnostics among others.

Why Purchase the Report?
• To visualize the global severe combined immunodeficiency (SCID) diagnosis market segmentation based on disease type, test type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of severe combined immunodeficiency (SCID) diagnosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global severe combined immunodeficiency (SCID) diagnosis market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies